Cargando…
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
The success of chimeric antigen receptor-modified T-cell (CAR-T) therapy for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both hematological and solid tumors. However, the two types of tumor are quite different in the following respec...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309774/ https://www.ncbi.nlm.nih.gov/pubmed/30636882 http://dx.doi.org/10.2147/OTT.S190336 |